This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use

Investment Opportunity - 'Discover' more about Absynth

7 September 2017

Absynth Biologics, a company set on addressing the healthcare challenges of life-threatening bacterial infections with its innovative vaccines is now in the 'discover' phase on the Capital Cell Platform (Capital Cell is a successful European life sciences funding platform recently launched in the UK).

HIGHLIGHTS

  • Absynth antigens are truly novel and harness both antibody and T cell responses
  • There are no marketed vaccines for our primary targets S. aureus (MRSA) and C. difficile; market estimates exceed $1 billion for each
  • Absynth patents are granted in all major territories, which underpins the value in our business
  • The management team have successful track records in anti-infectives which includes achieving high value exits for investors.

 THE PROJECT

Antimicrobial resistance is a serious challenge to modern medicine. Absynth develops vaccines to prevent bacterial infections occurring. Prevention of bacterial infection directly reduces the need for antibiotics, and prophylactic vaccines have never induced resistance.

Absynth’s vaccines target Staphylococcus aureus (S. aureus), which causes a range of illness from minor skin infections such as impetigo, boils and abscesses; to life threatening conditions such as pneumonia, meningitis and sepsis; and Clostridium difficile (C. difficile) which causes diarrhoea, fever and vomiting. MRSA is an antibiotic resistant form of S. aureus.

Absynth is competitively placed with a suite of novel protein vaccine antigens to prevent infections occurring, that differ from and offer possible benefits over competitor products.

THE PROBLEM

The healthcare problem addressed by Absynth is life-threatening infections by bacteria such as S. aureus (MRSA) and C. difficile for which there are currently no marketed vaccines. These infections occur in hospital patients but are now emerging in the community. Antibiotics are currently used to treat such infections but resistance to antibiotics is developing at an alarming rate.

THE SOLUTION

By preventing infections, vaccines reduce both mortality and antibiotic use, directly combating the problem of anti-microbial resistance. Prophylactic vaccines have never been known to induce resistance. Vaccines comprise sub-units of bacteria (antigens) to generate an immune response in a person without infection. Absynth antigens are novel and have been selected for specific properties which will give a highly effective immune response.

For more information please click here.